STOCK TITAN

Alimera Sciences, Inc. - $ALIM STOCK NEWS

Welcome to our dedicated page for Alimera Sciences news (Ticker: $ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alimera Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alimera Sciences's position in the market.

-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences earnings
Alimera Sciences, Inc.

Nasdaq:ALIM

ALIM Rankings

ALIM Stock Data

191.17M
8.06M
8.75%
91.96%
0.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ALPHARETTA

About ALIM

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.